Fig. 3

The comparison of the ration of the patients with the common adverse reactions (hypertension, hand-foot syndrome, and fatigue) and without them during anlotinib and combined with ICIs treatment in EGFR gene negative NSCLC. Then, stratification analysis of PFS of anlotinib between patients with and without the common adverse reactions. A The ratio of the patients with hypertension between anlotinib and combined with ICIs treatment was 50% and 58.9%, respectively (P = 0.049). B PFS of patients with and without hypertension in EGFR gene negative NSCLC was 5.7 months and 1.4 months (P < 0.0001). C The ratio of the patients with hand-foot syndrome between anlotinib and combined with ICIs treatment was 47.4% and 38%, respectively (P = 0.118). D PFS of patients with and without hand-foot syndrome was 4.9 months and 2.1 months (P = 0.431). E The ratio of the patients with fatigue between anlotinib and combined with ICIs treatment was 31.5% and 40.9% (P = 0.465). F PFS of patients with and without fatigue was 5.3 months and 3.2 months (P = 0.575)